Business Wire

2022 Blue Planet Prize: Announcement of Prize Winners - THE ASAHI GLASS FOUNDATION

15.6.2022 05:00:00 EEST | Business Wire | Press release

Share

This year marks the 31st awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two winners, individuals or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors have selected the following 2022 Blue Planet Prize recipients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220608006214/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

2022 recipients: (1) His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan; (2) Professor Stephen Carpenter (USA) (Graphic: Business Wire)

2022 recipients

His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan
Born in the Kingdom of Bhutan, Date of Birth: 11 November, 1955
His Majesty Jigme Singye Wangchuck, the Fourth King of Bhutan, is the visionary leader who introduced the development philosophy of Gross National Happiness (GNH) which places the well being of the people at the heart of development activities and programmes. GNH gives importance to environmental conservation, sustainable and equitable development, and promotion of culture and social values which contribute to collective happiness. Using happiness as a social indicator was taken on by the United Nations and OECD also employed it in their reports, giving inspiration for an alternative paradigm to modern society.

Professor Stephen Carpenter (USA)
Born in the USA, Date of Birth: 5 July, 1952
Emeritus Director of the Center for Limnology,
Stephen Alfred Forbes Professor Emeritus of Integrative Biology, University of Wisconsin-Madison
Professor Stephen Carpenter has conducted research on lake ecosystems for more than 40 years. Through his research on lake eutrophication, from nutrients such as phosphorus and nitrogen, he studied the resilience of lakes using mathematical models, providing a new perspective on social-ecological systems. He also worked on the environmental pollution from phosphorus and nitrogen through land use, showing the critical state of the global phosphorus cycle and the need to review human activity from a broad geochemical viewpoint.

Each recipient is presented with a certificate of merit, a commemorative trophy, and 50 million Japanese yen in prize money.
We would like to hold the Blue Planet Prize Award Ceremony and commemorative lectures, which could well be on a smaller scale, while taking proper measures to prevent infection with the new coronavirus. The Award Ceremony is scheduled on Wednesday, October 5, 2022 at Tokyo Kaikan. Commemorative lectures will be given on October 6 and 8, 2022, at the University of Tokyo and at Kyoto University, respectively.
This press release and the photo of each recipient will be published 11 a.m. on Wednesday June 15 on the website of the Asahi Glass Foundation (www.af-info.or.jp/en).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

THE ASAHI GLASS FOUNDATION
Toshihiro Tanuma, PhD
TEL: +81 3 5275 0620
FAX: +81 3 5275 0871
E-mail: post@af-info.or.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye